Hana Pharm Co Ltd (293480) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Hana Pharm Co Ltd KRW 10,896, price KRW 8,160, upside +33.5%, quality 52 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Hana Pharm Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
Hana Pharm Co., Ltd. develops and provides various pharmaceutical products in South Korea and internationally.
Show more
Hana Pharm Co., Ltd. develops and provides various pharmaceutical products in South Korea and internationally. It offers anesthetics, narcotic analgesics, antiemetics, muscle relaxants, cardiovascular and endocrine system, gastrointestinal system, respiratory system, antibiotics, dermatology, urinology, osteoporosis, and central nervous system products, as well as analgesics, antipyretics, and anti-inflammatory drugs. The company was founded in 1996 and is headquartered in Seoul, South Korea.
Stock analysis
Hana Pharm Co Ltd (293480) currently trades at 8,160 KRW, while our model-based Fair Value estimate is 10,896 KRW, implying the stock looks roughly 25.1% undervalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of 11,848 KRW per share, and 10 of the 14 models we run sit above the 8,160 KRW price.
Bear case: the Earnings-Based group reads lowest at 3,165 KRW, and 4 of the 14 models stay below the price. Evidence for this calculation is medium.
Scenario range: 8,172 KRW (bear) to 12,417 KRW (bull), the price of 8,160 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 52/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Hana Pharm Co Ltd reported revenue of 240B KRW in FY2025 versus 196B KRW in FY2021, a compound +5.1%/yr. Reported net income was 8.8B KRW in FY2025, compounding −25.2%/yr from FY2021.
Key figures
Market cap 141B KRW (≈ $104M) · P/S ratio 1.08 · Dividend yield 3.2% · Net margin 3.7% · Return on equity 35.5% · Return on assets (EBIT) 8.3% · Operating margin 22.8% · Revenue (TTM) 139B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 39 out of 100 (low confidence).
What moves the price
The share trades about 32% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at 34%, 293480 screens cheaper than that median.
Fair Value models
Bear 8,172 KRWFair Value 10,896 KRWBull 12,417 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.50/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+6.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.2%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.5%
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−1.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year−5.1%
Dividend (yield on the price)3.2%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.18% → 11%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 629 stocks
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Hana Pharm Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/293480
Frequently asked questions
Is Hana Pharm Co Ltd (293480) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 10,896 KRW versus a price of 8,160 KRW, about +34% upside (undervalued).
What is the fair value of 293480?
Our model-based fair value for Hana Pharm Co Ltd is 10,896 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 8,160 KRW.
What is the quality score of 293480?
Hana Pharm Co Ltd has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Hana Pharm Co Ltd (293480)?
Our model-based price target is the fair value of 10,896 KRW (as of Sep 24, 2026) from 14 valuation models. Cautious scenario 8,172 KRW, optimistic scenario 12,417 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Hana Pharm Co Ltd stock forecast for 2026?
Our models put fair value at 10,896 KRW, about +34% upside versus a price of 8,160 KRW (undervalued). Cautious scenario 8,172 KRW, optimistic scenario 12,417 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Hana Pharm Co Ltd (293480)?
Hana Pharm Co Ltd reported trailing-twelve-month revenue of about 139B KRW (latest available figure, as of Sep 24, 2026).
Does Hana Pharm Co Ltd pay a dividend?
Hana Pharm Co Ltd currently shows a dividend yield of about 3.19% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Hana Pharm Co Ltd (293480)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Hana Pharm Co Ltd it is 10,896 KRW per share (as of Sep 24, 2026), against a price of 8,160 KRW. It is the blended result of 14 valuation models (cash flow, earnings, asset, dividend).
Is Hana Pharm Co Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 293480 trades below its calculated fair value: price 8,160 KRW, fair value 10,896 KRW, a gap of about +34% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 293480?
No. The price is what the market pays today (8,160 KRW); the fair value is what the company's own numbers justify (10,896 KRW). For Hana Pharm Co Ltd the two are 2,736 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Hana Pharm Co Ltd worth?
The market values Hana Pharm Co Ltd at about 141B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 8,160 KRW; our models calculate a fair value of 10,896 KRW per share.
What do the bullish and bearish scenarios say about 293480?
Our models span a range for Hana Pharm Co Ltd: cautious scenario 8,172 KRW, base 10,896 KRW, optimistic 12,417 KRW per share (as of Sep 24, 2026, price 8,160 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Hana Pharm Co Ltd (293480)?
Balance-sheet figures for Hana Pharm Co Ltd (as of Sep 24, 2026): return on equity 35.5%, debt of 0.07 per unit of equity. They feed the Quality Score of 52/100, which measures business quality independently of the share price.
How far is 293480 from its 52-week high?
Hana Pharm Co Ltd trades at 8,160 KRW, about 32% below its 52-week high of 12,019 KRW and at the low of 8,150 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 10,896 KRW is for.
Which stocks are comparable to Hana Pharm Co Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Hana Pharm Co Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 8,160 KRW, calculated fair value 10,896 KRW (+34%), Quality Score 52/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 293480 calculated?
We run Hana Pharm Co Ltd through 14 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 10,896 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Hana Pharm Co Ltd currently trades 34 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Hana Pharm Co Ltd (293480)?
The closing price on Sep 23, 2026 was 8,160 KRW. Our model-based fair value is 10,896 KRW, about +34% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Hana Pharm Co Ltd right now?
Solid quality (52/100) at a price below fair value, the discount is the argument here, not the business quality. The price sits below our cautious bear case: the market assumes less than even our pessimistic scenario. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of Hana Pharm Co Ltd
How large is the market capitalisation of Hana Pharm Co Ltd (293480)?
The market capitalisation of Hana Pharm Co Ltd is 141B KRW (≈ $104M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Hana Pharm Co Ltd (293480)?
The price-to-sales ratio of Hana Pharm Co Ltd is 1.08 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Hana Pharm Co Ltd (293480)?
The dividend yield of Hana Pharm Co Ltd is 3.2%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Hana Pharm Co Ltd (293480)?
The net margin of Hana Pharm Co Ltd is 3.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Hana Pharm Co Ltd (293480)?
The return on equity (ROE) of Hana Pharm Co Ltd is 35.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Hana Pharm Co Ltd (293480)?
On an EBIT basis the return on assets of Hana Pharm Co Ltd is 8.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Hana Pharm Co Ltd (293480)?
The operating margin of Hana Pharm Co Ltd is 22.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does Hana Pharm Co Ltd (293480) generate?
The free cash flow of Hana Pharm Co Ltd is −22.0B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Hana Pharm Co Ltd (293480) carry?
The net debt of Hana Pharm Co Ltd is 46.4B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Hana Pharm Co Ltd in the live analysis
One click puts Hana Pharm Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
